Zura Bio Limited (ZURA)
NASDAQ:ZURA
Want to see ZURA full AI Analyst Report?
Top Page
Zura Bio
(NASDAQ:ZURA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-31.15% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak operating performance and rising cash burn, reinforced by bearish technical signals (negative MACD and price below key moving averages). Offsetting this, the company’s low-debt balance sheet and recent financing that extends runway, along with ongoing Phase 2 progress and leadership additions, provide support but do not fully counterbalance the current lack of revenue and continued losses.
Positive Factors
Low Leverage / Conservative Balance Sheet
Zero reported debt and a substantial equity base materially reduce solvency risk for a pre-revenue biotech. Low leverage gives management flexibility to prioritize R&D and strategic partnerships without near-term interest burden, supporting sustained investment through mid-stage development.
Negative Factors
High and Widening Cash Burn
Sustained negative operating and free cash flows reflect heavy R&D and G&A spend to advance mid-stage trials. Continued high burn rates can exhaust runway absent new funding, force dilutive financings, and constrain strategic optionality if trial timelines or enrollment stretch longer than planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Conservative Balance Sheet
Zero reported debt and a substantial equity base materially reduce solvency risk for a pre-revenue biotech. Low leverage gives management flexibility to prioritize R&D and strategic partnerships without near-term interest burden, supporting sustained investment through mid-stage development.
Read all positive factors
Zura Bio (ZURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$414.19M
Dividend YieldN/A
Average Volume (3M)679.53K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS Growth-60.98%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding94,997,710
10 Day Avg. Volume688,394
30 Day Avg. Volume679,528
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.14K
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$16.40Price Target Upside182.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Zura Bio Business Overview & Revenue Model
Company Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways;...
How the Company Makes Money
As a clinical-stage biotechnology company, Zura Bio does not have established product sales revenue. Its funding has primarily come from financing activities typical for pre-commercial biopharma companies (e.g., raising capital through equity offe...
Zura Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -81.45M | -75.20M | -55.18M | -62.64M | -27.16M | 8.42M |
| Net Income | -75.43M | -68.65M | -52.40M | -60.36M | -25.74M | 8.42M |
Balance Sheet | ||||||
| Total Assets | 228.64M | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Cash, Cash Equivalents and Short-Term Investments | 225.59M | 109.41M | 176.50M | 99.81M | 1.57M | 729.22K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.76M | 0.00 |
| Total Liabilities | 11.74M | 12.41M | 19.51M | 21.29M | 27.32M | 10.35M |
| Stockholders Equity | 216.90M | 101.54M | 146.81M | 59.33M | -32.06M | 130.20M |
Cash Flow | ||||||
| Free Cash Flow | -72.75M | -64.93M | -28.15M | -23.05M | -13.20M | -1.10M |
| Operating Cash Flow | -72.67M | -64.81M | -28.08M | -15.05M | -1.20M | -1.10M |
| Investing Cash Flow | -77.00K | -113.00K | -5.08M | -8.00M | -12.00M | -139.38M |
| Financing Cash Flow | 127.78M | -2.16M | 109.84M | 121.29M | 14.77M | 141.21M |
Zura Bio Technical Analysis
Negative
5.81
Price Trends
5.38
Negative
5.71
Negative
4.45
Negative
Market Momentum
-0.34
Positive
38.19
Neutral
33.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Negative. The current price of 5.81 is above the 20-day moving average (MA) of 4.78, above the 50-day MA of 5.38, and above the 200-day MA of 4.45, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 38.19 is Neutral, neither overbought nor oversold. The STOCH value of 33.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZURA.
Zura Bio Risk Analysis
Zura Bio disclosed 82 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zura Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $360.37M | -21.64 | 20.37% | ― | -2.38% | -37.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $776.48M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
49 Neutral | $414.19M | -6.89 | -54.60% | ― | ― | -60.98% | |
46 Neutral | $257.82M | -4.47 | -80.61% | ― | 43.21% | -15.55% | |
45 Neutral | $164.36M | -2.71 | -86.47% | ― | -23.73% | -44.36% |
* Healthcare Sector Average
ZURA
Zura Bio
4.36
3.36
336.00%
PBYI
Puma Biotechnology
7.08
3.64
105.81%
PRQR
ProQR
1.56
-0.14
-8.24%
CLLS
Cellectis SA
3.50
2.04
139.73%
VOR
Vor Biopharma
14.33
10.86
312.97%
Zura Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Zura Bio Reports Q1 Results, Advances Phase 2 Programs
Positive
May 7, 2026
On May 7, 2026, Zura Bio reported first-quarter 2026 results, highlighting continued progress in two Phase 2 tibulizumab trials in hidradenitis suppurativa and systemic sclerosis, as well as ongoing evaluation of additional indications and other p...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Zura Bio Reports 2025 Results, Extends Cash Runway Outlook
Positive
Mar 19, 2026
On March 19, 2026, Zura Bio reported its full-year 2025 results, highlighting progress in two ongoing Phase 2 trials of tibulizumab in hidradenitis suppurativa and systemic sclerosis, with HS topline data expected in late 2026 and SSc data in the ...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program
Positive
Mar 10, 2026
On March 10, 2026, Zura Bio Ltd., a clinical-stage biotechnology company developing therapies for complex immune disorders, released an updated corporate presentation highlighting its lead asset tibulizumab, a first-in-class bispecific antibody in...
Business Operations and StrategyProduct-Related Announcements
Zura Bio Highlights TibuSURE Phase 2 Trial Design
Positive
Mar 5, 2026
On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation at the 9th Systemic Sclerosis World Congress in ...
Business Operations and StrategyPrivate Placements and Financing
Zura Bio Raises Capital Through Expanded Equity Offering
Positive
Feb 26, 2026
On February 24, 2026, Zura Bio entered into an underwriting agreement to sell 18.2 million Class A ordinary shares and 1.8 million pre-funded warrants at a public price of $6.25 per share, with the warrants priced at $6.249. The offer was conducte...
Business Operations and StrategyExecutive/Board Changes
Zura Bio Strengthens Board with Immunology and R&D Leaders
Positive
Feb 23, 2026
On February 21, 2026, Zura Bio reshaped its board, with longtime director Neil Graham resigning and seasoned immunology and drug development executives Mark Eisner and Ajay Nirula joining as new directors. The appointments, confirmed in a February...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.